Diabetic neuropathy

EQS-News: Grünenthal reports strong 2023 results with record revenue and continued investments in R&D and acquisitions

Retrieved on: 
Wednesday, April 10, 2024
Trigeminal neuralgia, Knee, Growth, Rheumatoid arthritis, Neuropathic pain, Pain, GRM, DPN, ESG, Patient, Prednisolone, Research, Sustainalytics, Breakthrough, Glucocorticoid, Quality of life, PSNP, Research and development, Investment, Diabetic neuropathy, NOP, Kyowa Kirin, Osteoarthritis, RTX, Food, FDA, Corporation, Pharmaceutical industry

In 2023, Grünenthal generated €1.8 billion in revenues, an increase of 10 percent over the prior year.

Key Points: 
  • In 2023, Grünenthal generated €1.8 billion in revenues, an increase of 10 percent over the prior year.
  • Grünenthal owns 51 percent of the new enterprise Grünenthal Meds and intends to acquire the remaining share in 2026.
  • Aachen, Germany, 25 March 2024 – Grünenthal, the leading pharmaceutical company in pain research and management, released its 2023 full-year results, announcing a double-digit revenue growth.
  • The 2023 results were driven by strong business performance in the United States, Latin America and Europe.

Global Transdermal Medical Patch Market Analysis and Forecast to 2029: Growing Number of Smokers, Rising use for Insulin Delivery and Upswing in Hormonal Deficiencies Drives Demand - ResearchAndMarkets.com

Retrieved on: 
Monday, April 1, 2024
Medical Supplies, Retail, Health, Tobacco, General Health, Pharmaceutical, Biotechnology, Hypersensitivity, Plasma, Obesity, Growth, Prevalence, Rheumatoid arthritis, Application, Incidence, Diabetes, Patient, Pharmacy, Conditional sentence, Chronic pain, Stroke, Hospital, Smoker, Cancer, Nature, Migraine, Distribution, Arthritis, Nausea, Diabetic neuropathy, Smoking, Skin, Pain management, Pain, Allergy, Market, Vomiting, Osteoarthritis, Ageing, Pharmaceutical industry

The "Global Transdermal Medical Patch Market: Analysis By Type, By Application, By Distribution Channel, By Region Size & Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Transdermal Medical Patch Market: Analysis By Type, By Application, By Distribution Channel, By Region Size & Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.
  • The global transdermal medical patch market was valued at US$7.88 billion in 2023 and is expected to reach US$10.33 billion by 2029.
  • The global transdermal medical patch market is highly competitive in nature, characterized by fierce competition among industry leaders vying to expand their market presence.
  • The key players in the global transdermal medical patch market are:

Texas Original Announces Opening of Sugar Land Location, Launches New RSO Gummies

Retrieved on: 
Wednesday, March 27, 2024
Vitamins, Supplements, Tobacco, Cannabis, Alternative Medicine, General Health, Pharmaceutical, Health, Retail, Natural Resources, Oncology, Dark, Epilepsy, Spasticity, Cannabinoid, RSO, Patient, Flavonoid, Cancer, Terpene, Protein, Originality, THC, Physician, PTSD, Diabetic neuropathy, Medicinal plants

Texas Original , Texas’ leading medical cannabis provider, today announced the opening of its newest prescription pickup location in Sugar Land, Texas.

Key Points: 
  • Texas Original , Texas’ leading medical cannabis provider, today announced the opening of its newest prescription pickup location in Sugar Land, Texas.
  • Texas Original also announced the launch of its new Pineapple Gummies, a 20 mg THC-only product made with Rick Simpson Oil (RSO).
  • Alongside the company’s recently launched Dark Chocolate Bites and RSO Tincture, Texas Original’s Pineapple Gummies are among the first medical cannabis products in the state—and the first gummy product—to incorporate RSO.
  • Texans can obtain medical cannabis prescriptions through online clinics or local physicians registered with the Compassionate Use Registry of Texas.

Dr. Mark Silver Offers Options to Avoid Back Surgery

Retrieved on: 
Friday, March 22, 2024
General Health, Health, Surgery, Neurology, Nervous system, Nerve, Pain, Patient, Neurosurgery, Brain, Spinal cord stimulator, Diabetic neuropathy, Back pain, Dentistry

Dr. Mark Silver , founder of the Silver Spine and Neurological Center , offers treatments that can help many patients avoid the need for surgery to address back pain.

Key Points: 
  • Dr. Mark Silver , founder of the Silver Spine and Neurological Center , offers treatments that can help many patients avoid the need for surgery to address back pain.
  • “Surgery can be an effective form of back pain management,” said Dr. Mark Silver.
  • “But there are many other treatments that can avoid the need for surgery and should be considered.”
    Dr. Mark Silver is an expert on Neuromodulation, techniques that act directly on the nervous system.
  • By changing the way a patient’s nerves carry information to and from the brain, pain can be decreased and mobility improved.

Charles River and Navega Therapeutics Announce Comprehensive Gene Therapy Manufacturing Collaboration

Retrieved on: 
Thursday, March 14, 2024
Research, Medical Devices, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Erythromelalgia, AAV, Diabetic neuropathy, CDMO, Patient, CRL, Good manufacturing practice, Gene, DNA, CAP, Chronic pain, Doctor of Philosophy, GMP, Navega, Therapy, Peripheral neuropathy, CGT, Pharmaceutical industry

Charles River Laboratories International, Inc. (NYSE: CRL) and Navega Therapeutics , Inc., a biotechnology company developing epigenetic gene therapies, today announced an AAV9 production program agreement.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) and Navega Therapeutics , Inc., a biotechnology company developing epigenetic gene therapies, today announced an AAV9 production program agreement.
  • As part of Charles River’s Cell and Gene Therapy (CGT) Accelerator Program (CAP), Navega will have access to established contract development and manufacturing (CDMO) capabilities and advisory services to produce an adeno-associated virus (AAV)-based gene therapy, NT-Z001, for Phase I clinical trials.
  • To bring NT-Z001 to clinic, Navega will leverage Charles River’s off-the-shelf plasmid products, custom plasmid capabilities, and Good Manufacturing Practice (GMP)-grade AAV production.
  • Join Ana Moreno, CEO, Navega Therapeutics on March 19 in San Francisco – see the full agenda and save your seat: https://bit.ly/3SW3VOV
    “The collaboration with Navega will tap into our premier gene therapy CDMO capabilities and robust AAV offerings.

EMUAID® Unveils Breakthrough Natural Pain Relief Cream, Now Available at Walgreens Nationwide

Retrieved on: 
Tuesday, March 26, 2024
Cream, Arthralgia, Allantoin, First aid, Nonsteroidal anti-inflammatory drug, Arthritis, Arnica, Myalgia, Pain management, Pain, Steroid, Emu oil, Diabetic neuropathy, Cosmetics

This marks a significant expansion of EMUAID®'s reach in providing effective, natural alternatives for topical pain management to consumers nationwide.

Key Points: 
  • This marks a significant expansion of EMUAID®'s reach in providing effective, natural alternatives for topical pain management to consumers nationwide.
  • EMUAID® announces the launch of its innovative Pain Relief Cream in Walgreens stores across the United States.
  • The availability of EMUAID®'s Pain Relief Cream in the First Aid section at Walgreens strengthens the brand's accessibility, making it easier for consumers to experience the benefits of natural pain relief.
  • EMUAID® Pain Relief Cream is now available in the First Aid Section at Walgreens stores nationwide.

Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024

Retrieved on: 
Thursday, March 7, 2024
EDT, Master of Science, MD, Diabetic neuropathy, Notalgia paresthetica, FRCPC, Therapy, Webcast, Patient, Diagnosis, Itch, Epidemiology, KOL

The event will feature a panel of leaders in the field of neuropathic pruritus who will discuss the epidemiology, diagnosis, treatment landscape, and significant unmet medical need in notalgia paresthetica (NP).

Key Points: 
  • The event will feature a panel of leaders in the field of neuropathic pruritus who will discuss the epidemiology, diagnosis, treatment landscape, and significant unmet medical need in notalgia paresthetica (NP).
  • The live panel discussion will be moderated by Joana Goncalves, MD, Chief Medical Officer of Cara Therapeutics.
  • The event will also highlight oral difelikefalin in NP and its potential in this underserved neuropathy.
  • A live webcast of the event will be accessible under “Events & Presentations” in the Investors section of the Company’s website at www.CaraTherapeutics.com .

STATE OF CELIAC DISEASE IN CANADA - UNDERDIAGNOSED, UNAFFORDABLE AND UNSAFE FOOD: SURVEY

Retrieved on: 
Wednesday, February 28, 2024
Anxiety, Hospital, RISK, Restaurant, Genetic disorder, Radar, Diarrhea, Friends, Weight loss, Coeliac disease, Diabetic neuropathy, Federation, Malabsorption, Food, Increment, Risk, Frustration, HEALTH, Depression, Family, Headache, Disease, Migraine, Diagnosis, Child, Bloating, Brain, Dietary supplement

Twenty years after the first comprehensive survey of Canadians living with celiac disease, new results show the condition remains largely underdiagnosed, the gluten-free diet is often unaffordable, and many risk being exposed to unsafe food.

Key Points: 
  • Twenty years after the first comprehensive survey of Canadians living with celiac disease, new results show the condition remains largely underdiagnosed, the gluten-free diet is often unaffordable, and many risk being exposed to unsafe food.
  • Celiac Canada surveyed 7,500 Canadians with celiac disease on topics like what symptoms they experience, how long they went before being diagnosed, and how they manage living with the disease (eating challenges in social settings, the availability and cost of gluten-free food, and the psycho-social challenges of managing celiac disease).
  • Have all provinces add blood tests for celiac disease to the standard requisition used by family doctors.
  • Help healthcare professionals better recognize the increasing neurological and mental health signs of celiac disease (neuropathy, migraines, depression, anxiety) and not just the traditional disease symptoms (like bloating, weight loss, diarrhea).

Neuropathy Action Foundation Launches White Paper on Future of Gene Therapy & Urges Innovative Policy Approaches to Ensure Patient Access

Retrieved on: 
Monday, March 4, 2024
IPN, Gene, FDA, Quality of life, Food, Diabetic neuropathy, Peripheral neuropathy, Risk, NAF, Cell therapy, Society, Leukemia, Policy, Patient

SANTA ANA, Calif., March 4, 2024 /PRNewswire/ -- The Neuropathy Action Foundation (NAF), a non-profit organization dedicated to ensuring neuropathy patients have access to the treatments necessary to improve their quality of life, today announced the release of a new white paper, "The Promise of Gene Therapy for Neuropathy and Rare Diseases." The white paper explores the transformative potential of gene therapy for neuropathy and other patients and details policy considerations to ensure equitable patient access to these revolutionary treatments.

Key Points: 
  • The white paper explores the transformative potential of gene therapy for neuropathy and other patients and details policy considerations to ensure equitable patient access to these revolutionary treatments.
  • "The promise of gene therapy is immense, particularly for patients with neuropathy and other conditions with limited or no treatment options.
  • Creating New Payment Models: Innovative payment models should offset the current exorbitant costs and uncertainties associated with gene therapy.
  • Despite its decades-long scientific foundation, gene therapy represents a shift in healthcare and the translation of gene therapy from laboratory research to clinical application remains in its infancy.

The Inner Circle Acknowledges, Brian McDonagh, MD as a Pinnacle Lifetime Member

Retrieved on: 
Friday, March 1, 2024
PIT, University College Dublin, Inner circle, Medicine, MD, Diabetic neuropathy, Quality of life, Peripheral neuropathy, Hope, Neurology, Life, Disease, Alternative medicine, Bachelor, McDonagh, Relaxation, Attention, Patient, Carpal tunnel syndrome, Family, Multiple sclerosis, Crohn's disease, Beauty, Nursing

NORTHFIELD, Ill., March 1, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Brian McDonagh, MD is acknowledged as a Pinnacle Lifetime Member for his contributions to the Medical field.

Key Points: 
  • NORTHFIELD, Ill., March 1, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Brian McDonagh, MD is acknowledged as a Pinnacle Lifetime Member for his contributions to the Medical field.
  • Dr. Brian McDonagh, MD, is a renowned medical professional known for his exceptional contributions to the field of medicine, particularly in the treatment of Multiple Sclerosis (MS) and peripheral neuropathy.
  • The neurologist is celebrated for his innovative medical breakthroughs, which have transformed the lives of patients suffering from MS, Crohn's Disease, and Peripheral Neuropathy.
  • The doctor's journey to medical excellence began at University College Dublin, where he earned his Bachelor's degree and MD.